• Capstone Therapeutics disclosed about 21,750,000 shares outstanding as of Aug. 25, 2026, setting the base for total voting rights.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-029046), on August 27, 2026, and is solely responsible for the information contained therein.